CryoPort Inc (CYRX)

[H2R]

Supports 70 Ph 3, 25 MAA or BLAA til EoY 22

Our pipeline of commercial customers is the largest in our history. We’re now supporting 582 regenerative medicine clinical trials was 70 of them in Phase 3, approximately 30% of our pipeline is allogeneic of which 32 are in Phase 3.

We’re currently supporting eight commercial therapies and regenerative medicine. And for the remainder of this year, we anticipate up to another four MAA or BLA submissions for Cryoport supported products. In 2022, we’re looking for up to 21 additional filings. On the financial front, our total revenue in the third quarter of 2021 was a record $56.7 million, up from $11.2 million in the same period of the prior year.

On an organic basis that is without acquisitions, this translates into 38% year-over-year growth as we’re total revenue and the period, our Biopharma/Pharma business continues to be strong accounting for approximately 81%. Overall, we had a revenue increase of 371% over the third quarter of 2020.

CC Nov 4, 2021